Skip to main content

MoneyWorks4Me

Lupin informs about press release

07 Feb 2018 Evaluate

Lupin has informed about press release titled ‘Lupin and Yoshindos JV - YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1761.80
Dr. Reddys Labs. 1316.45
Cipla 1343.30
Lupin 1950.00
Zydus Lifesciences 1170.00
View more..